WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2 Recruiting 164 enrolled Mediar Therapeutics

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Timeline

Start: 2025-05-05
Primary completion: 2027-08
Completion: 2027-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MTX-463	Monoclonal antibody	—	Intravenous

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Summary

Timeline

Drugs

Indications